ClinicalTrials.gg
RecruitingNCT07255274SLEEP-OBUpdated Dec 1, 2025

Overweight and Obesity in Adolescents - Sleep Behavioral Intervention

An interventional study of Sleep Behavioral Intervention and Standard Obesity Treatment in Obesity and Overweight and Sleep Disorder, sponsored by University of Beira Interior. Recruiting at 2 sites in Portugal. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by University of Beira Interior · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Obesity with a site in Portugal — 26 open to participants now, 32 under way, 12 of them phase 3. Obesity · Portugal.

Planned enrollment
35th of 62
126 · median 150
Started
2025
with 9 others
No phase
35 of 68
14 open now
Primary completion
2026-06
later than 11 of 31 live
Registered
53rd of 68
by date

Among the 68 studies in Obesity with a site in Portugal, this one is the 35th largest by planned enrollment of the 62 interventional ones that give a count, is one of 10 that started in 2025, is one of 35 with no phase, reaches primary completion later than 11 of the 31 other live ones, and was the 53rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

26 of the 68 studies in Obesity with a site in Portugal are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Obesity with a site in Portugal, or all of them as a file.
02

Study summary

Sleep plays a crucial role in energy balance, alongside diet and physical activity. Research has linked poor sleep quality and short sleep duration to obesity and cardiometabolic risk, such as insulin resistance and hypertension. The nature of this association is complex, and several mechanims have been suggested.

Scientific evidence suggests that sleep interventions may provide additional benefits in optimizing the effectiveness of overweight/obesity treatment in pediatric populations. Although some studies have explored this hypothesis, methodological heterogeneity hampers clear interpretation of the results.

The main goal of this clinical trial is is to evaluate the efficacy of a sleep behavioral intervention, combined with standard obesity treatment, in reducing adiposity (measured by BMI z-score, fat mass percentage, or fat-free mass index) in adolescents with overweight or obesity.

This randomized controlled trial will compare a control group receiving treatment as usual (or standard obesity treatment) with an intervention group receiving treatment as usual plus a sleep behavioral intervention.

Participants will be randomized into two groups: intervention and control. Throughout the study period, all medical consultations will include standard interventions focused on nutrition, physical activity/sedentary behavior, and other lifestyle factors. The sleep-focused intervention will be delivered by psychologists.

Participants will attend clinic visits every two months during the 6-month intervention period, and every three months during the subsequent 6-month follow-up period.

Read the detailed description

A randomized controlled trial (open-label, behavioral intervention) will be conducted at ULS Cova da Beira and Hospital CUF Porto, enrolling 126 adolescents (ages 13-17) diagnosed with overweight or obesity and poor sleep quality. Participants will be randomized into two groups: the intervention group (sleep behavioral intervention plus treatment as usual) and the control group (treatment as usual).

In addition to the primary aim, the researchers will evaluate several secondary outcomes, including the efficacy of the intervention in relation to: cardiometabolic risk, sleep patterns, eating patterns, physical activity level, emotional well-being/self-compassion, quality of life, leptin and ghrelin levels, and tryptophan and melatonin metabolism.

Throughout the study period, all medical consultations will include standard multicomponent behavioral intervention. The sleep behavioral intervention will be conducted by psychologists.

The intervention consists of seven cognitive-behavioral therapy (CBT) sessions over six months, focusing on sleep hygiene, self-monitoring, stimulus control, cognitive therapy, and relaxation techniques.

Data collection and analysis will include objective sleep assessment using actigraphy and a level 3 ambulatory sleep study. Blood samples will be collected at baseline, six months, and twelve months to analyze metabolic markers. From the samples collected at months 0 and 6, a portion will be appropriately stored for additional analysis at an external facility to quantify leptin, ghrelin, and tryptophan pathway metabolites.

Anthropometric and clinical assessments will include measurements of body mass index (BMI), waist circumference, body composition, and blood pressure. Validated questionnaires will be used to evaluate sleep patterns, eating behaviors, physical activity, quality of life, emotional well-being, and self-compassion.

It is anticipated that the sleep behavioral intervention combined with standard treatment will be more effective than standard treatment alone not only in reducing adiposity, but also in improving cardiometabolic risk, sleep patterns, eating patterns, physical activity, emotional well-being, self-compassion, and in regulating hormonal and metabolic pathways including ghrelin, leptin, and the tryptophan-melatonin axis, as outlined in the study hypotheses

The study also aims to clarify the role of ghrelin and leptin levels, as well as the tryptophan pathway, in the interaction between sleep and obesity and in the effects of the intervention

Emotional well-being and self-compassion are expected to mediate the response to obesity intervention and the sleep-obesity relationship, potentially influencing or influenced by the tryptophan metabolic pathway, particularly serotonin levels.

By deepening the knowledge about the relationship between sleep and obesity, this research may contribute to optimize interventions for pediatric obesity, which would have an unequivocal positive impact.

03

Conditions studied

  • Obesity and Overweight
  • Sleep Disorder

Keywords

  • Obesity
  • Sleep
  • Behavioral intervention
  • Adolescents
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. from legal guardians and assent/consent from the adolescent;
  2. Age between 13 and 17 years at the time of consent;
  3. Diagnosis of overweight ( z-score > 1 and ≤ 2) or obesity (BMI z-score > 2), according to WHO criteria;
  4. Sleep deprivation or poor sleep quality, based on the initial screening questionnaire.

Exclusion criteria

Exclusion Criteria:

  1. Secondary obesity (e.g., hypothalamic, genetic, or endocrine causes);
  2. Comorbid psychiatric or neurological disorders (e.g., epilepsy, autism spectrum disorder) that affect sleep;
  3. Current treatment with selective serotonin reuptake inhibitors (SSRIs) or other medications affecting sleep.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Control group

    Standard interventions focused on nutrition, physical activity/sedentary behavior, and other lifestyle aspects.

    Other: Standard Obesity Treatment

  • Experimental
    Intervention group

    Standard intervention plus sleep-focused intervention. The sleep intervention will be conducted by psychologists. These monthly sessions, delivered in person or via video call, will be scheduled on the same day as the medical consultation whenever possible. The session planning and objectives are outlined in the study protocol.

    Behavioral: Sleep Behavioral Intervention · Other: Standard Obesity Treatment

Interventions

  • BehavioralSleep Behavioral Intervention

    Our research team, composed by pediatricians with experience in Obesity and Adolescent Medicine, and clinical psychologists with experience in Sleep, Obesity, and Cognitive Behavioral Therapy (CBT), developed a specific manual for this project: "Behavioral Sleep Intervention - SLEEP-OB - Therapist Support Manual." The manual was adapted based on CBT models for adults and adolescents with insomnia and on CBT for adolescents with other sleep disorders and comorbidities, namely obesity. The behavioral intervention aims to promote sustainable changes in sleep. It includes behavioral strategies (such as sleep restriction, stimulus control), cognitive strategies (cognitive reappraisal/restructuring, cognitive control, paradoxical intention), mixed strategies (sleep education/hygiene, relaxation), self-monitoring, and problem identification and resolution. The intervention will take place over six months, with a total of seven sessions (in-person and by video call).

    Also known as: Sleep intervention, Cognitive Behavioral Therapy for sleep disorders

  • OtherStandard Obesity Treatment

    Standard obesity treatment for pediatric obesity according to international guidelines. It comprises pediatric appointments, and usually also nutrition and nursing appointments, every 2 to 3 months. These appointments include an anthropometric evaluation, physical examination and personalized multicomponent behavioral intervention with focus on nutrition, physical activity/sedentary behavior and other lifestyle recommendations. This standard intervention is common for both groups/arms.

    Also known as: treatment as usual

06

What researchers measure

Primary outcomes

  1. BMI z-score at 6 months

    Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.

    Time frame: 6 months

  2. BMI at 6 months

    Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.

    Time frame: 6 months

  3. Fat mass percentage at 6 months

    Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.

    Time frame: 6 months

  4. Fat-free mass index at 6 months

    Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).

    Time frame: 6 months

Secondary outcomes

  1. Participants achieving a BMI reduction ≥5%

    Percentage of participants achieving a BMI reduction ≥5% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  2. Participants achieving a BMI reduction ≥10%

    Percentage of participants achieving a BMI reduction ≥10% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  3. Change in Waist circumference centile

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. waist circumference in centimeters, and centiles according to Sharma AK, et al. Pediatr Res. 2015.

    Time frame: 6 months and 12 months

  4. Fat mass percentage at 12 months

    Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.

    Time frame: 12 months

  5. Fat-free mass index at 12 months

    Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).

    Time frame: 12 months

  6. BMI z-score at 12 months

    Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.

    Time frame: 12 months

  7. BMI at 12 months

    Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.

    Time frame: 12 months

  8. Change in Waist-to-height Ratio

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  9. Change in C-reactive protein

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  10. Change in Fasting Lipid: Total Cholesterol

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  11. Change in Fasting Lipid: LDL-cholesterol

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  12. Change in Fasting Lipid: HDL-cholesterol

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  13. Change in Fasting Lipid: Triglycerides

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  14. Change in centiles of Systolic and Diastolic Blood Pressure

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Blood pressure measured and centiles according to the American Academy of Pediatrics.

    Time frame: 6 months and 12 months

  15. Change in HbA1c

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

    Time frame: 6 months and 12 months

  16. Change in Glycaemic Category

    Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" 2 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: fasting plasma glucose (FPG) \<100 mg/dL and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥126 mg/dL and/or HbA1c ≥6.5%

    Time frame: 6 months and 12 months

  17. Change in HOMA-B

    Variation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).

    Time frame: 6 months and 12 months

  18. Change in HOMA-IR

    Variation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. R

    Time frame: 6 months and 12 months

  19. Change in Continuous metabolic syndrome score

    Variation between Visit 1 and Visit 4 and between Visit and Visit 6. Calculation according to Vukovic R, et al. PLoS One. 2017 Dec 6;12(12):e0189232.

    Time frame: 6 months and 12 months

  20. Change in Sleep quality

    Sleep quality assessed by the Pittsburgh Sleep Quality Index, at Visit 1and Visit 4, and at Visit 6.

    Time frame: 6 months and 12 months

  21. Change in sleep quality - actigrafy

    Sleep quality assessed by actigraphy and sleep diary, at Visit 1and Visit 4.

    Time frame: 6 months

  22. Change in Respiratory Sleep disorder

    Respiratory sleep disorder assessed by the Pediatric sleep questionnaire at Visit 1and Visit 4.

    Time frame: 6 months

  23. Change in Diet Quality

    Mediterranean Diet Quality assessed with KIDMED questionnaire, at Visit 1 and Visit 4.

    Time frame: 6 months

  24. Change in Eating behavior

    MEating behavior assessed with Eating Attitudes Test questionnaire, at Visit 1 and Visit 4.

    Time frame: 6 months

  25. Change in emotional well-being

    At Visit 1 and Visit 4: Emotional well-being assessed through the WHO-5.

    Time frame: 6 months

  26. Change in Quality of life

    At Visit 1 and Visit 4: Quality of life evaluated with the KIDSCREEN 52 questionnaire.

    Time frame: 6 months

  27. Change in self-compassion

    At Visit 1 and Visit 4: Self-compassion evaluated with the Self-Compassion Scale for adolescents.

    Time frame: 6 months

  28. Change in Physical activity

    Physical activity assessed with International Physical Activity Questionnaire for Adolescents, at Visit 1 and Visit 4.

    Time frame: 6 months

  29. Change in Physical activity - actigraphy

    Physical activity assessed by actigraphy, at Visit 1 and Visit 4.

    Time frame: 6 months

Other outcomes

  1. Tryptophan pathway metabolites measurement

    Levels of tryptophan, kynurenine, serotonin, and melatonin in plasma samples, by metabolomic analysis/ liquid chromatography, at baseline (Visit 1) and after the Intervention (Visit 4).

    Time frame: 6 months

  2. Leptin and ghrelin levels

    Levels of leptin and ghrelin will be measured in plasma samples using enzyme-linked immunosorbent assay (ELISA) at baseline (Visit 1) and after the intervention (Visit 4).

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
  • Unidade Local de Saúde Cova da Beira
    Covilha, Portugal
    Recruiting
    • Sofia Ferreira, MD · Contactana.sofia.ferreira@ubi.pt · +351275330000
    • Arminda Jorge, PhD in Medicine · Contactajorge@fcsaude.ubi.pt
    • Sofia Ferreira, Medical Doctor · Principal investigator
    • Marta Rodrigues, Medical Doctor, Master degree · Sub investigator
    • Nuno Lourenço, Medical Doctor, Master degree · Sub investigator
    • Arminda Jorge, PhD in Medicine · Sub investigator
    • Ana Serra, Master in Psychology · Sub investigator
  • Hospital CUF Porto
    Porto, Portugal
    Not yet recruiting
    • Carla Rêgo, PhD in Medicine · Contactcarlambssrego@gmail.com
    • Carla Rêgo, PhD in Medicine · Principal investigator
    • Carla Laranjeira, Medical Doctor · Sub investigator
    • Sofia Ramalho, PhD in Psychology · Sub investigator
    • Margarida Gouveia, Master student in Psychology · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data may be shared upon request, provided that all identifying information is removed to safeguard participant anonymity. This process upholds the confidentiality and privacy of participants, fully complying with ethical and legal standards for data protection.

Supporting information: Study protocol, Statistical analysis plan

Time frame: June 2026 to June 2027

Access criteria: The data supporting the findings of this study will be available upon request from the corresponding author. Each request will be reviewed by the research team and the Ethics Committees that approved the study to ensure compliance with ethical standards.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2025
First posted
Dec 1, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07255274
Lead sponsor
University of Beira Interior
Responsible party
ana sofia rodrigues ferreira (PhD student, University of Beira Interior) — Principal investigator
First posted
Dec 1, 2025
Start date
Jun 3, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion